EP Patent

EP0251315A2 — Naphthalene derivatives, process for their preparation and pharmaceutical compositions containing the same

Assigned to Tanabe Pharma Corp · Expires 1988-01-07 · 38y expired

What this patent protects

Naphthalene derivative of the formula: wherein Ring A is a substituted or unsubstituted benzene ring; each of R¹ and R² is a group of the formula: -OR⁵, -NHR⁵ or ; or either one of R¹ and R² is a lower alkoxy group and other one is a group of the formula: -OR⁵, -NHR⁵ …

USPTO Abstract

Naphthalene derivative of the formula: wherein Ring A is a substituted or unsubstituted benzene ring; each of R¹ and R² is a group of the formula: -OR⁵, -NHR⁵ or ; or either one of R¹ and R² is a lower alkoxy group and other one is a group of the formula: -OR⁵, -NHR⁵ or ; each of R³ and R⁴ is a lower alkoxy group, or one of R³ and R⁴ is a lower alkoxy group and the other is a hydrogen atom; R⁵ is a substituted alkyl group, a heterocyclic group, a cyclo­alkyl group, an alkyl group of at least 5 carbon atoms or alkenyl group; and each of R⁶ and R⁷ is hydrogen atom or a lower alkyl group and salts thereof are disclosed. Said naphthalene derivative (I) and its salts have excellent hypolipidemic activity and are useful for treatment or pro­phylaxis of hyperlipidemia and/or arteriosclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP0251315A2
Jurisdiction
EP
Classification
—
Expires
1988-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.